These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32938950)

  • 1. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.
    Mehta N; Maddineni S; Kelly RL; Lee RB; Hunter SA; Silberstein JL; Parra Sperberg RA; Miller CL; Rabe A; Labanieh L; Cochran JR
    Sci Rep; 2020 Sep; 10(1):15171. PubMed ID: 32938950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.
    Mehta N; Maddineni S; Mathews II; Andres Parra Sperberg R; Huang PS; Cochran JR
    Cell Rep; 2019 Sep; 28(10):2509-2516.e5. PubMed ID: 31484064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of VSIG3: The Ligand for VISTA.
    Xie X; Chen C; Chen W; Jiang J; Wang L; Li T; Sun H; Liu J
    Front Immunol; 2021; 12():625808. PubMed ID: 33841409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
    Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
    Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VISTA is an acidic pH-selective ligand for PSGL-1.
    Johnston RJ; Su LJ; Pinckney J; Critton D; Boyer E; Krishnakumar A; Corbett M; Rankin AL; Dibella R; Campbell L; Martin GH; Lemar H; Cayton T; Huang RY; Deng X; Nayeem A; Chen H; Ergel B; Rizzo JM; Yamniuk AP; Dutta S; Ngo J; Shorts AO; Ramakrishnan R; Kozhich A; Holloway J; Fang H; Wang YK; Yang Z; Thiam K; Rakestraw G; Rajpal A; Sheppard P; Quigley M; Bahjat KS; Korman AJ
    Nature; 2019 Oct; 574(7779):565-570. PubMed ID: 31645726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.
    Olbromski M; Mrozowska M; Piotrowska A; Smolarz B; Romanowicz H
    Cancer Immunol Immunother; 2024 Jun; 73(8):136. PubMed ID: 38833004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
    Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
    J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity.
    Moon TJ; Ta HM; Bhalotia A; Paulsen KE; Hutchinson DW; Arkema GM; Choi AS; Haynie MG; Ogunnaike L; Dever M; Wang LL; Karathanasis E
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
    Yuan L; Tatineni J; Mahoney KM; Freeman GJ
    Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.
    Ceeraz S; Eszterhas SK; Sergent PA; Armstrong DA; Ashare A; Broughton T; Wang L; Pechenick D; Burns CM; Noelle RJ; Vincenti MP; Fava RA
    Arthritis Res Ther; 2017 Dec; 19(1):270. PubMed ID: 29216931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
    Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
    Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VISTA Blockade Aggravates Bone Loss in Experimental Murine Apical Periodontitis.
    Yang F; Zhang Y; Chen Z; Zhang L
    Front Immunol; 2021; 12():738586. PubMed ID: 34691045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction.
    Mostböck S; Wu HH; Fenn T; Riegler B; Strahlhofer S; Huang Y; Hansen G; Kroe-Barrett R; Tirapu I; Vogt AB
    Front Immunol; 2022; 13():862757. PubMed ID: 35967294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
    Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXD3 Regulates VISTA Expression in Melanoma.
    Rosenbaum SR; Knecht M; Mollaee M; Zhong Z; Erkes DA; McCue PA; Chervoneva I; Berger AC; Lo JA; Fisher DE; Gershenwald JE; Davies MA; Purwin TJ; Aplin AE
    Cell Rep; 2020 Jan; 30(2):510-524.e6. PubMed ID: 31940493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VSIG-3 as a ligand of VISTA inhibits human T-cell function.
    Wang J; Wu G; Manick B; Hernandez V; Renelt M; Erickson C; Guan J; Singh R; Rollins S; Solorz A; Bi M; Li J; Grabowski D; Dirkx J; Tracy C; Stuart T; Ellinghuysen C; Desmond D; Foster C; Kalabokis V
    Immunology; 2019 Jan; 156(1):74-85. PubMed ID: 30220083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance.
    Schaafsma E; Croteau W; ElTanbouly M; Nowak EC; Smits NC; Deng J; Sarde A; Webber CA; Rabadi D; Cheng C; Noelle R; Lines JL
    Cancer Immunol Res; 2023 Jan; 11(1):38-55. PubMed ID: 36260656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance.
    ElTanbouly MA; Zhao Y; Nowak E; Li J; Schaafsma E; Le Mercier I; Ceeraz S; Lines JL; Peng C; Carriere C; Huang X; Day M; Koehn B; Lee SW; Silva Morales M; Hogquist KA; Jameson SC; Mueller D; Rothstein J; Blazar BR; Cheng C; Noelle RJ
    Science; 2020 Jan; 367(6475):. PubMed ID: 31949051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
    Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.